Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress.
Mowday AM, Guise CP, Ackerley DF, Minton NP, Lambin P, Dubois LJ, Theys J, Smaill JB, Patterson AV. Mowday AM, et al. Among authors: patterson av. Cancers (Basel). 2016 Jun 28;8(7):63. doi: 10.3390/cancers8070063. Cancers (Basel). 2016. PMID: 27367731 Free PMC article. Review.
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
van der Wiel AMA, Jackson-Patel V, Niemans R, Yaromina A, Liu E, Marcus D, Mowday AM, Lieuwes NG, Biemans R, Lin X, Fu Z, Kumara S, Jochems A, Ashoorzadeh A, Anderson RF, Hicks KO, Bull MR, Abbattista MR, Guise CP, Deschoemaeker S, Thiolloy S, Heyerick A, Solivio MJ, Balbo S, Smaill JB, Theys J, Dubois LJ, Patterson AV, Lambin P. van der Wiel AMA, et al. Among authors: patterson av. Mol Cancer Ther. 2021 Dec;20(12):2372-2383. doi: 10.1158/1535-7163.MCT-21-0406. Epub 2021 Oct 8. Mol Cancer Ther. 2021. PMID: 34625504 Free PMC article.
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.
Spiegelberg L, Houben R, Niemans R, de Ruysscher D, Yaromina A, Theys J, Guise CP, Smaill JB, Patterson AV, Lambin P, Dubois LJ. Spiegelberg L, et al. Among authors: patterson av. Clin Transl Radiat Oncol. 2019 Jan 18;15:62-69. doi: 10.1016/j.ctro.2019.01.005. eCollection 2019 Feb. Clin Transl Radiat Oncol. 2019. PMID: 30734002 Free PMC article.
E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications.
Mowday AM, Copp JN, Syddall SP, Dubois LJ, Wang J, Lieuwes NG, Biemans R, Ashoorzadeh A, Abbattista MR, Williams EM, Guise CP, Lambin P, Ackerley DF, Smaill JB, Theys J, Patterson AV. Mowday AM, et al. Among authors: patterson av. Theranostics. 2020 Aug 21;10(23):10548-10562. doi: 10.7150/thno.46826. eCollection 2020. Theranostics. 2020. PMID: 32929365 Free PMC article.
Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours.
Mowday AM, Dubois LJ, Kubiak AM, Chan-Hyams JVE, Guise CP, Ashoorzadeh A, Lambin P, Ackerley DF, Smaill JB, Minton NP, Theys J, Patterson AV. Mowday AM, et al. Among authors: patterson av. Cancer Gene Ther. 2022 Feb;29(2):178-188. doi: 10.1038/s41417-021-00296-7. Epub 2021 Feb 8. Cancer Gene Ther. 2022. PMID: 33558701
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP, Mowday AM, Ashoorzadeh A, Yuan R, Lin WH, Wu DH, Smaill JB, Patterson AV, Ding K. Guise CP, et al. Among authors: patterson av. Chin J Cancer. 2014 Feb;33(2):80-6. doi: 10.5732/cjc.012.10285. Epub 2013 Jul 12. Chin J Cancer. 2014. PMID: 23845143 Free PMC article. Review.
107 results